Site search

Presentations

  1. HOME > 
  2. Presentations

Corporation Presentations

BrightPath Corporate Presentation - April 2023(4.5KB)

Recent Events

November 2023- SITC 2023

【HER2-CAR-T】PiggyBac transposon-mediated HER2-CAR-T cells exert anti-tumor efficacy against cholangiocarcinoma. (1.1MB)

【HER2 CAR-iNKT】 iPSC-derived CAR-iNKT cells targeting HER2 show prolonged tumor control and promote durable survival in a tumor xenograft model. (1.0MB)

November 2022- SITC 2022

【iPS-NKT】 A novel iPSC-derived CAR-invariant natural killer T (iNKT) cell therapy platform for hematologic malignancies and solid tumors(1.4MB)

【BP1202】 BP1202-NF2, a novel ADCC-enhancing CD39 antibody, induces destruction of regulatory T cells and enhances cytotoxic T lymphocytes induction(937KB)

【BP1212】 Bispecific antibodies that block TIM-3 and CD39 induce anti-tumor efficacy and immune response by blocking multiple suppressive mechanisms(739KB)

May 2022- Adenosine-Pathway Targeted Cancer Immunotherapy Summit

【BP1200,BP1202】 Targeted Inhibition of Adenosine Pathway by Humanized Antibodies to Enhance the Cancer Immunity

April 2022- AACR 2022

【BP2301】 Development of piggyBac transposon mediated HER2-CAR-T cells for the treatment of solid tumors(9.0MB)

【BP1200】 A novel anti-CD73 therapeutic antibody that ameliorates the tumor microenvironment and improves the efficacy of cancer immunotherapy(4.5MB)

【BP1209】 Personalized neoantigen cancer vaccine assembled on DC targeting antibody improves cancer immunity(2.3MB)

【BP1209】 A novel computational pipeline supported with in vivo T cell induction data for identification and validation of neoantigens(1.3MB)

January 2022- Cancer Science(publication)

【BP1209】 Development of antigen-prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse　　Cancer Science 2022 Apr;113(4):1113-1124.(10.9MB)

November 2021- SITC 2021

【BP1210】 Novel biparatopic TIM-3 antibody effectively blocks multiple inherent ligands and activates anti-tumor immunity(1.1MB)

September 2021- ESMO 2021

【BP1200】 A novel therapeutic antibody against CD73 that ameliorates the tumor microenvironment and improves the efficacy of cancer immunotherapy(4.5MB)

【BP1209】 A new platform of personalized neoantigen cancer vaccines directed by checkpoint inhibitor antibodies to improve cancer immunity(5.6MB)

Get Adobe Reader

Adobe Reader is required to view these PDF files

Page Top

×